S Bank Fund Management Ltd Has $2.26 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• S Bank Fund Management Ltd increased its stake in Zoetis Inc. by 14.9% during the second quarter, bringing its ownership to 14,481 shares valued at approximately $2.26 million.
• Zoetis recently reported $1.76 earnings per share for the quarter, surpassing expectations, and indicated a revenue increase of 4.2% year-over-year.
• The company announced a quarterly dividend of $0.50, with a payout ratio of 34.42%, payable on December 2nd to investors of record by October 31st.

S Bank Fund Management Ltd grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 14.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,481 shares of the company's stock after purchasing an additional 1,879 shares during the quarter. S Bank Fund Management Ltd's holdings in Zoetis were worth $2,258,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC acquired a new stake in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank acquired a new stake in Zoetis during the 1st quarter worth $29,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the period. Finally, REAP Financial Group LLC raised its stake in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock worth $31,000 after buying an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

ZTS opened at $142.08 on Thursday. The business's 50-day moving average price is $148.89 and its two-hundred day moving average price is $154.03. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55. The company has a market capitalization of $62.97 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 2.30 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the business posted $1.56 EPS. The company's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis's payout ratio is currently 34.42%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZTS. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.